Walgreens Slashes 2019 Outlook, Shares Dip 12%
The company's second-quarter report showed the continuing impact of shrinking generic drug sales on the country's largest pharmacy chains.
Companies Plead for New Pharma Supply Model
The long-entrenched system of drug-manufacturer rebates has not adapted to changes in health-plan designs and labor-market trends.
Shire Accepts Improved $62B Bid From Takeda
The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.
Teva to Cut 14,000 Jobs in ‘Drastic’ Overhaul
The drugmaker says "there is no alternative" to its restructuring plan amid pricing pressure on its core generics business.
Teva Stock Drops 24% on Q2 Earnings Miss
The company's revenue rose 13% but the core generics business experienced "accelerated price erosion and decreased volume."
Mylan Underpaid U.S. on Rebates for EpiPen
A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
Rite Aid Posts 22% Revenue Increase
But the drugstore chain's same store-sales fell short of estimates in part due to the introduction of low-margin generic drugs.